#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage II Blastic plasmacytoid dendritic cell neoplasia Transferrin decreased Selective polysaccharide antibody deficiency Systemic lupus erythematosus Chronic cutaneous lupus erythematosus Chemical burn Glomerulonephritis MELAS syndrome Bulbospinal muscular atrophy congenital Metastatic gastric cancer Mucopolysaccharidosis I Non-small cell lung cancer recurrent Neuroblastoma Nasopharyngeal cancer More trials…

    Learn about Rare Diseases

    Richter’s syndrome – Life with Disease Rosai-Dorfman syndrome – Treatment Haemophilia B without inhibitors – Life with Disease Primary immunodeficiency syndrome Small intestine leiomyosarcoma – Basic Information Rhabdomyosarcoma – Diagnostics Glycogen storage disease type V Encephalitis autoimmune – Trials in Disease Leiomyosarcoma metastatic Synovial sarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hypothalamic Phospholipids Zanamivir Mk-0616 GSKVX000000044501 Vesleteplirsen Rucaparib Vutrisiran Oxacillin Lisinopril Dihydrate D5-Ethyl-Beta-D-Glucuronide Sasanlimab Filgotinib Iodine (123I) Iobenguane Meldonium Gad20-209-Fsp-A4 Rifabutin Linperlisib Retinol Acetate Betula Verrucosa (108) Lactose Monohydrate More therapies…

    Learn about Your Condition

    Procedural headache Febrile neutropenia Psoriatic arthropathy Osteoarthritis Pancreatic carcinoma Paget's disease of the vulva Liposarcoma Cortisol abnormal Chronic coronary syndrome Carotid arteriosclerosis Vaginal haemorrhage Weaning failure Malignant mast cell neoplasm Arrhythmia supraventricular Foetal growth restriction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myasthenia gravis

  • Study on Long-Term Safety and Effectiveness of Zilucoplan in Adults with Generalized Myasthenia Gravis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • ZILUCOPLAN
    Italy Norway Poland Spain

  • Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Belgium France Germany Italy Poland +1

  • Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Cyprus Czechia Denmark Finland France +9

  • Study on the Safety and Effectiveness of Rozanolixizumab in Children with Generalized Myasthenia Gravis

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Immunoglobulins, Normal Human
    • Rozanolixizumab
    Italy Poland

  • Study on the Safety and Effectiveness of Rozanolixizumab and Immunoglobulins in Children with Generalized Myasthenia Gravis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Immunoglobulins, Normal Human
    • Rozanolixizumab
    Italy Poland

  • Study on Ublituximab and Drug Combination for Patients with Myasthenia Gravis or Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Cetirizine
    • Ublituximab
    • Dexamethasone
    Poland
Previous Page
1 … 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!